Lv4
488 积分 2024-12-12 加入
Discovery Processof Enlicitide, a Highly EngineeredMacrocyclic Peptide Therapeutic, through Issue-Driven Fragment-BasedSynthetic Assembly and SAR
20天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
30天前
已完结
Protocols for the Induction and Evaluation of Systemic Anaphylaxis in Mice
1个月前
已完结
Immunology of anaphylaxis: Lessons from murine models
1个月前
已完结
Mast cells chill in anaphylaxis
1个月前
已完结
Cytokine release assays: Current practices and future directions
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
1个月前
已完结
Development of RMC-6236, a potent and orally bioavailable RAS(ON) multi-selective tri-complex inhibitor for the treatment of RAS-addicted cancers by targeting multiple RAS variants
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
皖公网安备34019202002308
